Answers are grounded in this paper and cite their sources.
Bortezomib treatment prevents tissue and body weight loss during fasting. The loss of proteasome activity with bortezomib exacerbates fasting-induced ketogenesis. During fasting, bortezomib increases AMPK and PI3K/AKT signaling in the liver, which promotes protein synthesis.
No takes yet. Share an insight, caveat, or question.
Langer et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: